Blood Biomarker May Help Verify CT-Captured Lung Cancer
Researchers have found a blood biomarker that can complement LDCT by distinguishing NSCLC from benign nodules without an invasive biopsy.
Read MorePosted by Chris Wolski | Jul 13, 2022 | Lung Cancer |
Researchers have found a blood biomarker that can complement LDCT by distinguishing NSCLC from benign nodules without an invasive biopsy.
Read MorePosted by Andy Lundin | Jul 7, 2022 | Company News, Lung Cancer |
Medial EarlySign signed a new partnership with Roche to create innovative, evidence-based solutions for early detection of lung cancer.
Read MorePosted by Chris Wolski | Jun 10, 2022 | Lung Cancer |
FoundationOne CDx has been approved by the FDA to be used as a companion diagnostic for the two indications of Rozlytrek (entrectinib).
Read MorePosted by Andy Lundin | Jun 6, 2022 | Lung Cancer |
A simple blood test could be an ideal predictor of whether cancer immunotherapy will be successful for a lung cancer patient.
Read MorePosted by Andy Lundin | May 30, 2022 | Lung Cancer |
CorePath is partnering with Cizzle Biotechnology to develop and offer a proprietary early-stage lung cancer blood test for the U.S.
Read More